Pediatrix Medical Group, Inc. (MD) Stock News

AMD stock has surged 160% in 2026 and nearly reached $600 per share in late June, but analyst Keithen Drury argues the stock is overvalued. Trading at 61x forward earnings compared to Nvidia's 30.2x, AMD has priced in nearly two years of growth despite solid 38% YoY revenue growth and expected 44% growth for 2026. While AMD's data center division grew 57% YoY, the analyst suggests investors can find better values elsewhere in the market.

Nvidia is rapidly gaining market share in the server CPU market with its Grace and newly launched Vera processors, which claim significant performance advantages over Intel and AMD's x86-based chips. While Intel and AMD currently dominate with combined data center revenues around $50 billion annually, Nvidia is projected to capture $20 billion in Vera server CPU revenue this fiscal year alone. Analysts predict Arm-based CPUs could capture nearly 90% of the server CPU market by 2029, potentially threatening Intel and AMD's growth momentum.

AMD is positioned to capture significant market share in AI accelerators with major contracts from Microsoft, Meta, OpenAI, and Anthropic providing multi-year revenue visibility. Wall Street projects AMD's revenue to grow from $50B in 2026 to over $100B by 2028, with EPS rising from $7.50 to $20. Even with P/E compression from current levels of 64 to 48-52, the stock could appreciate up to 101% by 2028.

AMD is gaining ground in the AI chip market with major partnerships including deals with Anthropic, Microsoft Azure, OpenAI, and Meta, plus securing workloads from Turing. However, Nvidia still dominates with 80% market share and $75B in quarterly data center revenue compared to AMD's 5-7% market share. The article suggests both companies can grow substantially in the estimated $200B AI accelerator market by 2026, with AMD stock up 158% YTD versus Nvidia's 12% gain.

AMD CEO Lisa Su has strategically positioned the company as a major AI winner through major deals with OpenAI, Meta, Anthropic, and Microsoft for GPU deployments, innovative chiplet designs for inference workloads, and expansion into server CPUs. With agentic AI expected to shift GPU-to-CPU ratios and AMD targeting a $220 billion server CPU market with 50% market share, the company is positioned for significant growth.

VAST Data announced an expanded collaboration with AMD to deliver high-performance AI infrastructure combining VAST's AI Operating System with 6th Gen AMD EPYC CPUs and AMD Instinct GPUs. The partnership includes optimized KV cache management, reference architectures, and demonstrated 9X speedup in time-to-first-token for agentic AI workloads. Leading AI cloud providers including Core42, Crusoe, Vultr, and others are adopting the combined solution.

Outlook Therapeutics announced FDA approval of LYTENAVA™ (bevacizumab-vikg), the first FDA-approved ophthalmic formulation of bevacizumab specifically designed for treating wet AMD. The approval provides 12 years of market exclusivity under BPCIA and positions the company to capture market share in the approximately $8.5 billion U.S. retina market. The company is launching commercial operations and expects to make LYTENAVA™ available to patients before year-end.

Cathie Wood's Ark Innovation ETF has been selling AMD and buying SpaceX, but analyst Geoffrey Seiler argues this is the wrong move. SpaceX trades at extreme valuations (P/S ratio over 85x) with significant technological hurdles ahead and upcoming share dilution from lock-up expirations. AMD, meanwhile, is positioned to benefit from powerful trends in AI inference and agentic AI, with secured GPU deals and strong CPU demand driving near-term growth.

Schneider Electric and AMD announced a jointly developed reference design for AMD's Helios rackscale solution to accelerate AI Factory deployment. The design supports high-density AI clusters up to 10.4 MW IT load with 246 kW per rack, advanced liquid cooling achieving PUE as low as 1.12, and integrated digital infrastructure management tools for faster, lower-risk deployment of AI environments.

Embedded LLM launched TokenVisor Spaces, a new product that combines AMD EPYC CPUs for agent execution with AMD Instinct GPUs for inference, providing governed, auditable agentic AI services. The solution addresses enterprise needs for stateful agent execution, policy enforcement, and cost-effective long-context inference through KV-cache reuse, validated on AMD infrastructure with significant performance improvements.

AMD and Cerebras announced a technical partnership to deliver a disaggregated AI inference solution combining AMD Helios rackscale solutions with Cerebras Wafer-Scale Engine technology. The joint solution is designed to deliver ultra-low latency for advanced AI applications while increasing throughput and efficiency, with expected availability through Cerebras Cloud in the second half of 2026.

AMD has secured Microsoft as a major customer for its Helios rack-scale server platform, with deployment beginning in the second half of 2026. This partnership, following Meta's earlier adoption, positions AMD to capture significant share in the rapidly growing AI server market expected to reach $838 billion by 2030. The news could drive stronger-than-expected Q2 earnings results on Aug. 4.

AMD stock surged 7.91% after expanding its partnership with Microsoft to deploy Helios rack-scale systems on Azure cloud computing for AI inference workloads. The integrated system combines AMD's Instinct GPUs, Venice CPUs, and networking solutions to reduce AI application costs. Despite Nvidia's dominance with over 90% market share in data center AI chips, AMD's cost-efficient approach could help it gain market share in the rapidly expanding AI market.

The Roundhill Memory ETF (DRAM) has doubled since its spring 2026 launch, outperforming major AI chip makers by focusing on high-bandwidth memory (HBM), which has become the critical bottleneck in AI supply chains. The ETF holds ~20 memory companies with 75% concentrated in Samsung, SK Hynix, and Micron, benefiting from tight HBM supply and strong pricing power. However, the fund carries significant risks including extreme concentration, high volatility, geopolitical exposure, and the cyclical nature of memory markets.

While both Nvidia and AMD have benefited from AI accelerator demand, their business strategies diverge significantly. Nvidia has concentrated 92% of revenue in data center AI chips, achieving 85% revenue growth and trading at 31x earnings. AMD maintains a more diversified portfolio across CPUs, GPUs, and embedded chips, with 56% from data center and 35% from client/gaming segments, posting 38% revenue growth but trading at a higher 161x P/E ratio. Nvidia's first-mover advantage and lower valuation make it the more attractive buy despite AMD's solid diversification strategy.

4D Molecular Therapeutics (4DMT) announced positive 2-year results from its PRISM Phase 2b clinical trial of 4D-150, an intravitreal gene therapy for wet age-related macular degeneration (AMD). The single-dose treatment demonstrated consistent maintenance of visual acuity and anatomic control with 78-87% reduction in treatment burden compared to standard aflibercept injections. The therapy was well-tolerated with no new safety concerns or intraocular inflammation cases beyond the first 6 months.

KeyBanc set a $725 price target on AMD, implying a 40% gain, but analyst Keithen Drury argues this is overly optimistic. AMD trades at a premium valuation despite lagging Nvidia in AI accelerators and lacking the profit margins to justify current prices. Even under highly optimistic scenarios, AMD would trade at 36x forward earnings, making Nvidia the better investment.

AMD reports Q2 earnings on Aug. 4 with high expectations for 47% revenue growth. The stock has surged 130% in 2026 and trades at a 75x forward P/E ratio, making it vulnerable to disappointment. Nvidia, trading at only 24x forward earnings despite faster expected growth (~100%), could benefit if AMD confirms strong AI demand. Analysts suggest Nvidia offers better value than AMD at current valuations.

Kalaris Therapeutics announced positive Phase 1a data for TH103, its investigational treatment for neovascular AMD. The expanded trial of 17 treatment-naive patients showed improvements in vision and retinal anatomy, with 29% requiring no additional anti-VEGF treatment during six-month follow-up. TH103 demonstrated 27-53 fold lower plasma levels compared to leading anti-VEGF agents while maintaining efficacy. The company is actively enrolling patients in Phase 1b/2 trials with preliminary data expected in H1 2027.

Medicare issued a favorable local coverage determination (LCD) for donor-derived cell-free DNA (dd-cfDNA) testing, expanding reimbursement for transplant organ monitoring. The policy increases surveillance testing frequencies across kidney and heart transplants compared to previous guidelines, supporting iMDx's commercial strategy for in-house testing kits. The company's flagship GraftAssureCore test is reimbursed at $2,753 per result, while GraftAssureDx awaits FDA marketing authorization.

As AI inference becomes the next major market opportunity, three chipmakers are competing for dominance. Nvidia leverages its CUDA ecosystem and acquired Groq's LPUs for inference workloads. Cerebras offers faster wafer-scale chips but at premium costs. AMD is positioned as the strongest contender, combining inference capabilities with its MEXT acquisition for memory optimization and benefiting from agentic AI's CPU demand growth.

AMD is positioned to deliver strong Q2 earnings on Aug. 4 due to surging demand for server CPUs driven by agentic AI and inference workloads. The CPU-to-GPU ratio in AI data centers is shifting from 1:4-1:8 toward 1:1-1:2, potentially increasing server CPU demand by 4x. AMD has gained market share (33% in Q1 2026 vs. 27.2% year-ago) and is raising prices, with server CPU prices up 10-20% between March-April. Despite a rich valuation (186x trailing earnings), AMD's ability to outperform expectations could sustain its momentum.

AMD's partnership with 5C to collaborate on next-gen data center construction strengthens its position as a viable direct competitor to NVIDIA. The deal transforms AMD from a hardware vendor into a full-stack operator capable of delivering hyperscale data centers with advanced cooling systems on a turnkey basis. Analysts view this positively, with 44 analysts covering AMD and a consensus price target trending toward $700 (25% upside). Key risks remain valuation at 75x current-year outlook and execution, though forecasts suggest double-digit hypergrowth and potential $200 billion revenue within the next decade.

Silo Pharma announced that its subsidiary QwikAgents has been accepted into Advanced Micro Devices' AMD AI Developer Program. The acceptance provides access to AMD Developer Cloud credits, AI development tools, and technical resources to support QwikAgents' next-generation AI agent platform designed for individuals, developers, small businesses, and enterprises.

AMD is expected to deliver bullish guidance during its Q2 2026 earnings call on Aug. 4, driven by strong data center GPU demand and new MI450 series deployments from major customers like OpenAI and Meta. However, AMD's stock trades at a P/E ratio of 121.8—nearly four times higher than Nvidia's 32.2—making valuation a concern despite positive business fundamentals.

While Broadcom and AMD are often cited as competitive threats to Nvidia's AI dominance, the article argues that Nvidia's greatest risk comes from its own major customers developing internal AI chips. These in-house solutions are cheaper, more available, and could erode Nvidia's pricing power, gross margins, and upgrade cycles.

Nvidia's reported delay of its Kyber NVL144 AI rack system until 2028 due to circuit board manufacturing issues could create opportunities for competitors AMD and Alphabet. While Nvidia maintains its market dominance through aggressive technology roadmaps, physical manufacturing constraints may finally be catching up. AMD's improved ROCm platform and chiplet designs, along with Alphabet's optimized TPUs, position both companies to capture market share in the high-end AI infrastructure segment.

Comparing three AI chip leaders, Nvidia emerges as the best buy despite underperformance year-to-date, offering superior growth and attractive valuation. Broadcom is a solid alternative with strong 2027 growth prospects from custom AI chips for major hyperscalers. AMD, despite its 2026 rally, appears overvalued relative to its competitive position against Nvidia's dominant data center presence.

Intel and AMD stocks have declined sharply in early July after strong gains in 2026, but analyst Keithen Drury argues this is not a buying opportunity. Both companies are expensive turnaround plays that are significantly underperforming their dominant rivals—AMD versus Nvidia in GPUs and Intel versus TSMC in foundries. With valuations already pricing in future growth that may not materialize, the analyst recommends selling Intel and AMD in favor of their better-positioned competitors.

Developments from Samsung and DeepSeek sent semiconductor stocks lower on July 7, 2026. The article discusses how news from these companies impacted major chip manufacturers, with mixed market reactions across the sector.